ClinicalTrials.gg
RecruitingNCT06355063Updated Jan 12, 2026

CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation

An interventional study of CellFX® nsPFA™ Cardiac Surgery System in Atrial Fibrillation, Surgery and Ablation of Atrial Fibrillation, sponsored by Pulse Biosciences, Inc.. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Pulse Biosciences, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.

Planned enrollment
176th of 192
30 · median 250
Started
2024
with 12 others
No phase
106 of 255
19 open now
Primary completion
2026-12
later than 16 of 48 live
Registered
233rd of 255
by date

Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 176th largest by planned enrollment of the 192 interventional ones that give a count, is one of 13 that started in 2024, is one of 106 with no phase, reaches primary completion later than 16 of the 48 other live ones, and was the 233rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 255 studies in Atrial Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

This feasibility study will be conducted to demonstrate the initial safety and effectiveness of the CellFX® nsPFA™ Cardiac Clamp in performing a box lesion around the 4 pulmonary veins as an isolated procedure or as a part of a more extensive surgical ablation set in conjunction with concomitant cardiac surgical procedure.

Read the detailed description

This study is a prospective, multicenter, single arm, non-randomized, feasibility study. Adult subjects who are clinically indicated for a concomitant cardiac surgical procedure will undergo left pulmonary vein, roof and floor ablations to form a left atrial posterior box. All subjects will return to the hospital between 60-120 days post-surgical ablation procedure to undergo a cardiac electrophysiology study with electroanatomical mapping to assess electrical isolation of the pulmonary veins and left atrial posterior wall

03

Conditions studied

  • Atrial Fibrillation
  • Surgery
  • Ablation of Atrial Fibrillation
  • Clamp Study

Browse trials for

Keywords

  • CellFX
  • nsPFA Cardiac Surgery System
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be between 18 and 85 years of age
  • Subject is willing and capable of providing to undergo study procedures which includes surgical AF ablation and completing follow-up visits as specified in the clinical study protocol
  • Subject has history of documented atrial fibrillation within one year prior to enrollment. Documentation may include , transtelephonic monitor (TTM), holter monitor or telemetry strip
  • Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, or Coronary artery bypass procedures
  • ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
  • Subject has a of at least 5 years

Exclusion criteria

Exclusion Criteria:

  • Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or CRT) or left atrial appendage device
  • Subject has a prosthetic heart valve
  • Stand-alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery
  • Previous surgical Maze procedure
  • Prior cardiac surgery (Redo)
  • Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, Atrioventricular (AV) nodal reentry
  • Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair.
  • Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation)
  • Class IV (NYHA) heart failure symptoms
  • Prior history of cerebrovascular accident or within 6 months or at any time if there is residual neurological deficit
  • Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
  • Need for emergent cardiac surgery (i.e., cardiogenic shock)
  • Known carotid artery stenosis greater than 80%
  • Current diagnosis of active systemic infection
  • Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
  • Renal failure requiring dialysis or hepatic failure
  • A known drug and/or alcohol addiction
  • Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study
  • Pregnancy or desire to get pregnant within 12-months of the study treatment
  • Preoperative need for an intra-aortic balloon pump or intravenous inotropes
  • Subjects who have been treated with thoracic radiation
  • Subjects in current chemotherapy
  • Subjects on long term treatment with oral or injected (not including intermittent use of inhaled steroids for respiratory diseases)
  • Subjects with known hypertrophic obstructive cardiomyopathy
  • Subjects with known cold agglutinin
  • History of abnormal bleeding and/or clotting disorder
  • to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as warfarin)
  • Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  • > 40 kg/m2
  • Use of any other drug, therapy, or device within 30 days prior to enrollment or concurrent participation in another research study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CellFX nsPFA Treatment Arm

    Adult subjects who are clinically indicated for a concomitant cardiac surgical procedure will undergo left pulmonary vein, roof and floor ablations to form a left atrial posterior box using the CellFX® nsPFA™ Cardiac Surgery System.

    Device: CellFX® nsPFA™ Cardiac Surgery System

Interventions

  • DeviceCellFX® nsPFA™ Cardiac Surgery System

    Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.

06

What researchers measure

Primary outcomes

  1. Rate of acute major adverse events (MAEs)

    Acute major adverse events (MAEs) include, cardiac death, stroke, myocardial infarction, transient ischemic attack, or excessive bleeding.

    Time frame: Within 30 days post-ablation procedure

  2. Number of Participants with acute electrical isolation of the bilateral pulmonary veins and left atrial box

    The ablation procedure includes pulmonary vein isolation and a series of ablation lines to create a "box lesion" on the posterior left atrial free wall. At the conclusion of both the primary and concomitant procedures, exit and/or entrance block will be performed to confirm complete isolation of the pulmonary veins and the left atrial posterior wall.

    Time frame: Within 24 hours post-ablation procedure

Secondary outcomes

  1. Proportion of Participants with one or more SAEs

    Long-term safety endpoint for the incidence of treatment-emergent adverse events \[Safety and Tolerability\] for subjects having one or more SAEs at each follow-up interval.

    Time frame: Up to 12-months post-procedure

  2. Number of Participants with Long-Term Technical Success

    Long-term Technical Success of the Pulse Biosciences CellFX® nsPFA™ Cardiac Surgery System is defined as participants having confirmation of electrical isolation of the bilateral pulmonary veins and left atrial box by cardiac electroanatomical mapping 2-6 months post-ablation procedure.

    Time frame: 60-120 days following the index procedure

07

Study locations

4 of 6 sites recruiting
  • Medical University of Vienna
    Vienna, Austria
    Recruiting
    • Prof. Marek Ehrlich, M.D., Ph.D · Contact
    • Emilio Osario, MD · Sub investigator
  • Academic Medical Center
    Amsterdam, Netherlands
    Active, not recruiting

    Not enrolling at this site.

  • Catharina Hospital
    Eindhoven, Netherlands
    Recruiting
    • N.J. (Niels) Verberkmoes, MD · Contact
  • Maastricht University Medical Center+ (MUMC+)
    Maastricht, Netherlands
    Active, not recruiting

    Not enrolling at this site.

  • St. Antonius Hospital
    Nieuwegein, Netherlands
    Recruiting
    • Bart van Putte, MD, PhD · Principal investigator
  • State Medical Institute of the Ministry of Interior Affairs and Administration
    Warsaw, Poland
    Recruiting
    • Prof. Dr. Piotr Suwalski, M.D. Ph.D · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 29 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 9, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06355063
Lead sponsor
Pulse Biosciences, Inc.
Collaborators
Avania
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Jul 31, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

William A. Knape
Contact
bknape@pulsebiosciences.com
+1 (919) 757-2033
Aleksandra Kurek
Contact
aleksandra.kurek@pulsebiosciences.com
+44 745 6655949
Rich Nuccitelli, PhD
study director · Pulse Biosciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion